EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Five-year recurrence rate of cutaneous squamous cell carcinoma after Mohs micrographic surgery versus standard excision: a prospective multicentre cohort study

Celeste J Eggermont, Emmy C Crüts, Charlotte B van Lee, Hanke C de Vijlder, Leonie Jacobs, Leon C C Wijne, Ruud G L Nellen, Annik van Rengen, Tamar Nijsten, Marlies Wakkee, Nicole W J Kelleners-Smeets, Renate R van den Bos

British Journal of Dermatology · 2026-09-10

DOI: 10.1093/bjd/ljag399 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Mohs micrographic surgery (MMS) is a tissue-sparing alternative to standard excision (SE) for treatment of cutaneous squamous cell carcinoma (CSCC). Prospective studies comparing recurrence risk between MMS and SE remain limited, and no randomized controlled trials exist. In clinical practice, MMS tends to be selectively offered for higher-risk tumours in cosmetically sensitive areas. Objectives To compare 5-year recurrence rates between MMS and SE for primary CSCC, and to compare metastasis rates and the ratio of final defect size to initial tumour size. Methods This was a prospective multicentre cohort study of patients with primary CSCCs treated with MMS or SE in the Netherlands. To detect all recurrences, patients were linked to the Dutch Nationwide Pathology Databank. The Fine and Gray competing risk regression model was used to assess the subdistribution hazard ratio (sHR) for recurrence. Results A total of 761 patients with 903 completely excised primary CSCCs were included: 629 treated with SE and 274 with MMS. Tumours treated with MMS were more often classified as high stage according to the American Joint Committee on Cancer, eighth edition (AJCC 8) [≥ T2, 55.5% (n = 152/274) vs. 25.3% (n = 159/629); P < 0.001], and more frequently located in the H-zone [76.6% (n = 210/274) vs. 37.0% (n = 233/629), P < 0.001]. The 5-year cumulative incidence of recurrence was 1.7% (95% CI 0.9–3.0%) for SE and 3.3% (95% CI 1.6–5.9%) for MMS. After adjustment for AJCC 8 stage, the sHR for recurrence after MMS compared with SE was 1.51 (95% CI 0.66–3.44; P = 0.33). The 5-year cumulative incidence of metastasis was 0.8% (95% CI 0.3–1.8%) for SE and 1.1% (0.3–3.0%) for MMS. The ratio of final defect size to initial tumour size was smaller for MMS (1.2 vs. 3.0, P < 0.001). Conclusions No significant difference was found in 5-year recurrence rate between MMS and SE; however, definitive conclusions cannot be drawn about whether a true difference in efficacy exists. MMS resulted in smaller defects, supporting its use in cosmetically or functionally sensitive areas where tissue preservation is important.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →